| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
An ideal pharmaceutical treatment for abdominal aortic aneurysm (AAA) is to prevent aneurysm formation and development (further dilatation of pre-existing aneurysm). Recent studies have reported that oxidative stress with reactive oxygen species (ROS) is crucial in aneurysm formation. We have demonstrated that edaravone, a free-radical scavenger, attenuated vascular oxidative stress and inhibit AAA formation and development in rat AAA model. Based on the results, we also have proven the efficacy of other anti-oxidants, such as a gelatin hydrogel sheet incorporating ascorbic acid, a novel oral antidiabetic drug of Dipeptidyl peptidase-4 (DPP-4) inhibitor, and oral administration of riboflavin on the treatment of AAA.
|
